Peripheral zone (PZ) adenocarcinoma is the most common prostatic malignancy, accounting for 70-80% of all prostate cancers. PZ is the largest zone of the prostate gland (70%) and the most susceptible area for cancer development. Histologically characterized by atypical glandular proliferation, loss of basal cell layer, and stromal invasion. On mpMRI, the diagnostic triad consists of focal hypointensity in the normally hyperintense PZ on T2-weighted images, marked diffusion restriction on DWI, and low values on ADC map. According to PI-RADS v2.1 classification, primary assessment in PZ lesions is based on DWI/ADC, with DCE serving as an upgrading criterion. Gleason score (ISUP Grade Group) is determinative in prognosis and treatment planning. Early-stage disease (T1-T2) may be curable with radical prostatectomy or radiotherapy, while locally advanced (T3-T4) and metastatic disease requires androgen deprivation therapy (ADT) and chemotherapy.
Age Range
50-80
Peak Age
68
Gender
Male predominant
Prevalence
Common
Prostate adenocarcinoma originates from acinar (glandular) epithelium in the peripheral zone. Androgen receptor (AR) signaling pathway plays a central role in carcinogenesis — testosterone and dihydrotestosterone (DHT) stimulate tumor growth. In early stages, genetic alterations accumulate including TMPRSS2-ERG gene fusion (in ~50% of cases) and PTEN tumor suppressor gene loss. Tumor cells show dense packing and glandular lumen architecture is disrupted — this increased cellularity narrows the extracellular space and restricts free movement of water molecules, which manifests as diffusion restriction on DWI and low values on ADC map. The cause of T2 hypointensity is replacement of fluid-filled glandular lumens in normal PZ by dense tumoral cells — free water decreases, T2 relaxation time shortens. Neoangiogenesis (VEGF expression) leads to increased vascular permeability and early enhancement — observed as positive finding on DCE. In advanced stages, the tumor can invade through the prostatic capsule (extraprostatic extension, EPE), into periprostatic fat tissue, seminal vesicles (SVI), and adjacent organs.
The triad of focal T2 hypointense lesion in peripheral zone + marked diffusion restriction on DWI + low values on ADC is the diagnostic cornerstone of prostate adenocarcinoma on mpMRI. This triad forms the core of PZ assessment in PI-RADS v2.1 classification. DWI/ADC is the primary assessment criterion and T2 plays a supportive role.
Focal, well or poorly defined hypointense lesion in the normally homogeneously hyperintense T2 signal area of the peripheral zone. Signal intensity of the lesion is distinctly lower than surrounding normal PZ tissue. Lesion morphology can be round, oval, or irregular. Large lesions (≥15 mm) raise PI-RADS score to 4-5. Extraprostatic extension (EPE) findings — capsular irregularity, tumor extending beyond capsule, neurovascular bundle involvement, or rectoprostatic angle obliteration — are assessed as PI-RADS 5. Seminal vesicle invasion (SVI) appears as focal hypointense tumor extension in the normally hyperintense seminal vesicle on T2.
Report Sentence
A ___ mm focal hypointense lesion is noted in the peripheral zone on T2-weighted images, suspicious for prostatic adenocarcinoma.
On high b-value (b=1400-2000 s/mm²) DWI, the peripheral zone lesion shows markedly hyperintense signal — separates brightly from surrounding normal PZ tissue. According to PI-RADS v2.1, DWI is the primary assessment criterion in PZ: PI-RADS 3 = focal mild-moderate hyperintensity on DWI (size <15 mm), PI-RADS 4 = marked hyperintensity or size ≥15 mm, PI-RADS 5 = ≥15 mm and/or definite EPE/SVI. Signal intensity on DWI correlates with tumor Gleason score — high Gleason score tumors show brighter DWI signal.
Report Sentence
The peripheral zone lesion demonstrates marked diffusion restriction on high b-value DWI, raising high suspicion for clinically significant prostate cancer.
The peripheral zone lesion shows markedly low signal (dark area) on ADC map. The ADC threshold for clinically significant cancer (ISUP ≥2) is generally accepted as <800 × 10⁻⁶ mm²/s. In high-grade tumors (Gleason 4+4=8, ISUP 4-5), ADC values can drop to <600 × 10⁻⁶ mm²/s. There is an inverse correlation between ADC values and Gleason score — lower ADC indicates more aggressive tumor. According to PI-RADS v2.1, ADC together with DWI is the primary assessment criterion for PZ lesions. ADC value is also used in active surveillance decisions and treatment response evaluation.
Report Sentence
Markedly low ADC values are noted in the peripheral zone lesion on ADC map (ADC: ___ × 10⁻⁶ mm²/s), consistent with clinically significant prostate cancer.
The peripheral zone lesion shows focal, early, and intense enhancement on DCE MRI. While normal PZ tissue enhances slowly and homogeneously, adenocarcinoma rapidly enhances in the early arterial phase due to neoangiogenesis. According to PI-RADS v2.1, positive DCE can upgrade a PI-RADS 3 lesion in PZ to PI-RADS 4. DCE alone does not determine PI-RADS score, serving only as an upgrading criterion. Enhancement kinetic curve is typically Type III (washout) or Type II (plateau) pattern. Enhancement timing and intensity reflect the degree of tumor neovascularity.
Report Sentence
The peripheral zone lesion demonstrates focal early enhancement on DCE series (positive DCE), serving as an upgrading criterion in PI-RADS assessment.
On TRUS, peripheral zone adenocarcinoma classically appears as a hypoechoic lesion. However, approximately 30-40% of prostate cancers are isoechoic on TRUS and undetectable — therefore TRUS alone is insufficient as a screening modality. Hypoechoic lesions may show increased Doppler vascularity. The primary role of TRUS is providing guidance for prostate biopsy — MR-TRUS fusion biopsy technology is used to transfer mpMRI findings to TRUS-guided biopsy. TRUS is also used for prostate volume measurement and PSA density calculation.
Report Sentence
A ___ mm hypoechoic lesion with increased vascularity is noted in the peripheral zone on TRUS; MR-guided or MR-TRUS fusion biopsy is recommended.
Prostate adenocarcinoma shows intense PSMA expression on ⁶⁸Ga-PSMA PET-CT. PSMA (Prostate-Specific Membrane Antigen) is a transmembrane glycoprotein overexpressed 100-1000 fold in prostate cancer cells. Intense uptake is observed in the primary tumor, lymph node metastases, and bone metastases on PET-CT. PSMA PET-CT is used especially in biochemical recurrence (PSA elevation) to detect recurrence site, in primary staging (high-risk disease: Gleason ≥4+3, PSA >20, ≥T3), and treatment response evaluation. ¹⁸F-PSMA-1007 and ⁶⁸Ga-PSMA-11 are the most commonly used radiopharmaceuticals.
Report Sentence
Focal uptake with intense PSMA expression is observed in the prostatic peripheral zone on PSMA PET-CT, consistent with prostate adenocarcinoma; whole-body evaluation for lymph node and bone metastasis should be performed.
CT is limited in primary tumor evaluation of prostate cancer (insufficient soft tissue contrast) but plays an important role in staging. Contrast-enhanced CT evaluates pelvic and retroperitoneal lymph node metastases (short axis >8 mm obturator, >10 mm iliac/para-aortic), bone metastases (osteoblastic lesions — characteristic metastatic pattern of prostate cancer), and visceral metastases. Bone metastases appear as sclerotic (hyperdense) lesions on CT — common in axial skeleton (vertebrae, pelvis) and proximal long bones. In locally advanced disease, bladder base invasion, rectal wall involvement, and pelvic sidewall invasion can be evaluated.
Report Sentence
CT for staging purposes has been evaluated for pelvic and retroperitoneal lymph node metastasis and bone metastasis; osteoblastic lesions in vertebral bodies are suspicious for metastasis.
Criteria
Well-differentiated, low-grade adenocarcinoma
Distinct Features
Usually small, mildly T2 hypointense on mpMRI, mild restriction on DWI (PI-RADS 3). Active surveillance candidate — may not need treatment. ADC usually >1000
Criteria
Intermediate-grade adenocarcinoma — clinically significant cancer threshold
Distinct Features
Distinctly T2 hypointense on mpMRI, moderate-to-marked restriction on DWI (PI-RADS 4). ADC 600-900. Treatment required — radical prostatectomy or radiotherapy
Criteria
High-grade, aggressive adenocarcinoma
Distinct Features
Markedly hypointense on mpMRI, very marked restriction on DWI (PI-RADS 5). ADC <600. Frequently EPE/SVI positive. Staging with PSMA PET-CT recommended. Requires multimodal treatment
Distinguishing Feature
Prostatitis shows diffuse or wedge-shaped T2 hypointensity with striated enhancement, differing from the focal, round/oval lesion of adenocarcinoma. DWI restriction in prostatitis is milder and diffuse, ADC values usually >900. Clinically, fever, dysuria, and transient PSA elevation are distinguishing.
Distinguishing Feature
Granulomatous prostatitis can mimic adenocarcinoma with focal T2 hypointensity and DWI restriction in peripheral zone. History of BCG treatment or systemic granulomatous disease is an important clue. Biopsy is usually required as MR findings are indistinguishable from cancer.
Distinguishing Feature
Post-biopsy hemorrhage shows hyperintense signal on T1 (methemoglobin) and may be hypointense on T2 — mimicking adenocarcinoma. Hemorrhage is distinguished by high signal on T1-weighted images. mpMRI should be performed at least 6-8 weeks after biopsy.
Distinguishing Feature
Atrophy can show diffuse or focal T2 hypointensity in PZ. However, atrophy shows no DWI restriction and ADC values are normal or elevated. Atrophy is usually bilateral and symmetric with no mass effect.
Urgency
urgentManagement
surgicalBiopsy
NeededFollow-up
specialist-referralMR-guided or MR-TRUS fusion biopsy is recommended for PI-RADS 4-5 lesions. Treatment is planned based on Gleason score and stage: low risk (ISUP 1, PSA <10, ≤T2a) → active surveillance option; intermediate risk → radical prostatectomy or radiotherapy; high risk (ISUP ≥4, PSA >20, ≥T3) → multimodal treatment + ADT + staging with PSMA PET-CT. EPE/SVI presence is staged as ≥T3 and neoadjuvant/adjuvant therapy is considered. In metastatic disease, ADT + docetaxel or abiraterone combination is standard treatment.
PZ adenocarcinoma comprises the vast majority of prostate cancers. Gleason score (ISUP grade) is the most important prognostic determinant. mpMRI PI-RADS scoring guides biopsy decisions. Treatment options include active surveillance, radical prostatectomy, radiation therapy, and hormonal therapy.